Postmortem Toxicology Made Easy with Randox Drugs of Abuse Biochips
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
The analysis of postmortem blood is one of the most challenging tasks in forensic toxicology, but Randox can help through the development of its biochip array technology applied to multi-analyte screening. The Randox Drugs of Abuse (DoA) biochips permit the simultaneous analysis of up to 10 drug classes per array from a single blood sample.
Randox biochip array technology is based on ELISA principles. Each biochip (9mm x 9mm) contains discrete test regions (DTRs) into which capture antibodies specific to each drug class are immobilized and stabilized.
In addition, two DTRs are reserved on the biochip for quality control. Postmortem blood can be screened using biochips with a simple dilution of blood, eradicating the need for the lengthy and expensive sample clean up associated with postmortem blood.
Two DoA arrays are currently available. DoA Array I enables simultaneous determination of amphetamine, methamphetamine, barbiturates, benzodiazepine 1 & 2, cannabinoids, the cocaine metabolite benzoylecgonine, methadone, opiates and phencyclidine.
DoA Array II enables simultaneous determination of buprenorphine, fentanyl, generic opioids, oxycodone 1 and 2, ketamine, LSD, MDMA, methaqualone and propoxyphene. With as little as 60ml of diluted blood, the evaluation of the DoA arrays demonstrates excellent analytical performance.
The DoA assays are applicable to two revolutionary biochip analyzers. The fully automated Evidence (FDA cleared) has been designed for high throughput laboratories and will generate up to 900 test results per hour. Once samples are loaded onto the Evidence analyzer, the doors are locked and the PC interface is password protected providing chain of custody information. The semi-automated Evidence Investigator is suitable for medium size laboratories and will generate up to 540 test results in 80 minutes.
Randox biochip array technology is based on ELISA principles. Each biochip (9mm x 9mm) contains discrete test regions (DTRs) into which capture antibodies specific to each drug class are immobilized and stabilized.
In addition, two DTRs are reserved on the biochip for quality control. Postmortem blood can be screened using biochips with a simple dilution of blood, eradicating the need for the lengthy and expensive sample clean up associated with postmortem blood.
Two DoA arrays are currently available. DoA Array I enables simultaneous determination of amphetamine, methamphetamine, barbiturates, benzodiazepine 1 & 2, cannabinoids, the cocaine metabolite benzoylecgonine, methadone, opiates and phencyclidine.
DoA Array II enables simultaneous determination of buprenorphine, fentanyl, generic opioids, oxycodone 1 and 2, ketamine, LSD, MDMA, methaqualone and propoxyphene. With as little as 60ml of diluted blood, the evaluation of the DoA arrays demonstrates excellent analytical performance.
The DoA assays are applicable to two revolutionary biochip analyzers. The fully automated Evidence (FDA cleared) has been designed for high throughput laboratories and will generate up to 900 test results per hour. Once samples are loaded onto the Evidence analyzer, the doors are locked and the PC interface is password protected providing chain of custody information. The semi-automated Evidence Investigator is suitable for medium size laboratories and will generate up to 540 test results in 80 minutes.
